UN Secretary-General Guterres said immediate, substantial cuts in emissions are needed.

Phrontline Biopharma, a China-based antibody‑drug conjugate (ADC) developer, said it closed a Series A round of nearly $40m, bringing total new investment to about $100m over the past year. The round was led by Yuanhe Origin and Decheng Capital, with participation from Longpan Investment, Jifeng Capital, Mifang Health Fund, Songqing Capital and Jianfa Emerging Investment; Dianshi Capital served as exclusive financial adviser. Proceeds will accelerate clinical development of the core pipeline, support IND filings for differentiated reserve candidates, build a new payload platform and expand international collaborations and capitalization efforts.

【股指期貨午盤收盤】滬深300股指期貨（IF）主力合約跌1.26%，上證50股指期貨（IH）主力合約跌0.28%，中證500股指期貨（IC）主力合約跌2.73%，中證1000股指期貨（IM）主力合約跌3.44%。